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Background: It is unclear whether beta-blocker therapy should be reduced or withdrawn in patients who develop acute decompensated heart
failure (HF). We studied the relationship between changes in beta-blocker dose and outcome in patients surviving a HF hospitalisation in
COMET.
Methods: Patients hospitalised for HF were subdivided on the basis of the beta-blocker dose administered at the visit following hospitalisation,
compared to that administered before.
Results: In COMET, 752/3029 patients (25%, 361 carvedilol and 391 metoprolol) had a non-fatal HF hospitalisation while on study
treatment. Of these, 61 patients (8%) had beta-blocker treatment withdrawn, 162 (22%) had a dose reduction and 529 (70%) were maintained
on the same dose. One-and two-year cumulative mortality rates were 28.7% and 44.6% for patients withdrawn from study medication, 37.4%
and 51.4% for those with a reduced dosage (n.s.) and 19.1% and 32.5% for those maintained on the same dose (HR,1.59; 95%CI, 1.28–1.98;
pb0.001, compared to the others). The result remained significant in a multivariable model: (HR, 1.30; 95%CI, 1.02–1.66; p=0.0318). No
interaction with the beneficial effects of carvedilol, compared to metoprolol, on outcome was observed (p=0.8436).
Conclusions: HF hospitalisations are associated with a high subsequent mortality. The risk of death is higher in patients who discontinue beta-
blocker therapy or have their dose reduced. The increase in mortality is only partially explained by the worse prognostic profile of these patients.
© 2007 European Society of Cardiology. Published by Elsevier B.V.Keywords: Decompensated heart failure; Trials; Beta-blockers☆ Source of funding: COMET was supported by F Hoffmann La Roche
and GlaxoSmithKline.
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doi:10.1016/j.ejheart.2007.05.0111. Introduction
Randomised clinical trials have shown the beneficial ef-
fects of beta-blockers in the treatment of patients with rela-
tively stable, symptomatic chronic heart failure (HF) due
to left ventricular (LV) systolic dysfunction [1–6]. Despited by Elsevier B.V.
Fig. 1. Flow chart showing number of patients, follow-up and changes in study drug dosages for patients hospitalised for heart failure in COMET. Abbreviations:
C = carvedilol; M = metoprolol; HF = heart failure.
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 the benefits of medical treatment many patients progress to
advanced HF and are hospitalised for HF decompensation.
When this occurs, beta-blockers are often reduced or dis-
continued [7–9] as it is thought that this will improve
worsening dyspnoea, fatigue and/or hypotension, which may
be exacerbated by the short-term negative inotropic effects of
beta-blockade [10,11]. On the other hand, randomised
controlled trials have shown that the beneficial effects of
beta-blockers also occur among patients with severe HF.
[2,12–15] Randomised trials, however, include selected
patient populations. Even the patients included in the
Carvedilol Prospective Randomized Cumulative Survival
Study (COPERNICUS) had to be clinically stable with no
need of i.v. therapy for at least 4 days before randomisation.
We therefore have no definitive results about the effects of
beta-blocker therapy on outcome in patients who have been
recently hospitalised for decompensated HF.
In the Carvedilol orMetoprolol European Trial (COMET),
3029 patients with chronic HF were randomised to carvedilol
or metoprolol tartrate and followed up for a median of
58 months [16]. This trial represents a unique possibility to
assess the effects on outcome of a change in beta-blocker
therapy after an episode of HF hospitalisation. In the pres-
ent study we assessed the prognostic role of a change in the
beta-blocker dose after a HF hospitalisation in the COMET
patients.
2. Methods
The COMET design has been published [16,17]. In brief,
COMET was a multicenter, randomised, double-blind, par-
allel-group trial comparing the effect on mortality and mor-bidity of carvedilol and metoprolol tartrate in patients with
symptomatic chronic HF (NYHA class II–IV), LV ejection
fraction (EF)≤35%, at least one cardiovascular hospitalisa-
tion during the 2 years before trial entry, optimal baseline
therapy, including the need for diuretic therapy. COMETwas
designed as an event-driven study with the co-primary end-
points of all-cause mortality and the combined endpoint of
mortality or hospitalisation for any cause. Patients were ran-
domised to carvedilol or metoprolol tartrate and received
initial doses of 3.125 mg or 5 mg twice daily (bid) re-
spectively. Doses were doubled at 2 week intervals, aiming
for target doses of 25 mg bid of carvedilol and 50 mg bid of
metoprolol tartrate. When patients reached the target or the
maximally tolerated dose, the maintenance phase began.
During this phase, every patient underwent clinical assess-
ment every 4 months.
Hospitalisations were defined as any admission that re-
quired at least one overnight stay in the hospital [17,18]. The
causes of admission were classified by the investigator on
the case report form. Hospitalisations were differentiated
as cardiovascular or non-cardiovascular. Causes of cardio-
vascular hospitalisations included HF, unstable angina, sus-
pected myocardial infarction, stroke, or others. Three clinical
presentations of HF hospitalisations were considered:
worsening HF, acute pulmonary oedema and complications
of drug treatment. Since this last category included only a
few events (49 patients, 5.7%), unrelated to HF (hypoten-
sion, dizziness, bradycardia), we excluded them from data
analysis.
To assess the prognostic significance of the change in the
beta-blocker dose after a HF hospitalisation, we compared
the dose of beta-blocker administered at the visit following
Table 1
Baseline characteristics of COMET patients hospitalised for heart failure according to changes in study drug doses
All
n=752
Withdrawn or reduced
n=223
Unchanged
n=529
p value withdrawn or reduced
versus unchanged
Age (years) 64±11 65±10 64±11 0.278
Sex (% male) 76 70 78 0.025
Race (% white) 99 99 99 0.635
Body Mass Index
(kg/m2)
27±4 26±4 27±5 0.220
Systolic BP (mm Hg). 124±20 122±20 124±20 0.062
Diastolic BP (mm Hg) 76±11 75±11 76±11 0.445
Heart rate (bpm) 81±13 83±13 81±13 0.111
NYHA class (%)
II 40 32 42 0.035
III 56 63 53
IV 6 5 6
Duration CHF (months)
mean/median
51/32 53/30 51/32 0.574
Aetiology (%)
Ischaemic heart disease 60 58 60 0.608
Hypertension 18 13 20 0.032
Dilated cardiomyopathy 39 39 39 0.908
Previous valve surgery 4 2 4 0.197
LV ejection fraction (%) 25.1±7.2 24.1±7.0 25.5±7.3 0.018
NT-proBNP
(pg/ml) median
1890 2280 1771 0.797
Associated diagnosis (%)
Previous myocardial
infarction
48 49 48 0.948
CAD (by angiography) 65 67 64 0.470
Current angina 25 21 27 0.070
Hypertension 39 38 39 0.711
Diabetes 33 33 32 0.800
Stroke 9 8 9 0.763
ECG findings (%)
Sinus rhythm 71 69 72 0.294
Atrial fibrillation/flutter 22 23 21 0.554
Paced rhythm 8 9 8 0.563
% LBBB 6 7 6 0.651
Concomitant medications (%)
Diuretics 99 99 99 0.623
ACE Inhibitors 91 89 92 0.150
ARBs 6 6.7 5.7 0.577
Digitalis 62 66 60 0.097
Antiarrhythmics 14 17 12 0.083
Nitrates 39 35 41 0.010
Aldosterone antagonists 14 17 13 0.154
Beta-blockers 5 4 5 0.408
Anticoagulants 48 46 49 0.367
Aspirin 38 38 38 0.975
Statins 21 18 23 0.172
Abbreviations: % = percentage of patients; BP = blood pressure; CAD = coronary artery disease; CHF = heart failure; LV = left ventricular; LBBB = left bundle
branch block; ARBs = angiotensin receptor blockers; BB = beta-blockers; HR = heart rate. Beta-blockers refer to patients receiving beta-blockers before entry
into the trial.
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 the HF hospitalisation with the dose administered at the visit
before the HF hospitalisation. Patients were subdivided in
three groups: those who received the same dose before and
after the HF hospitalisation; those who had a dose reduction
of at least one level at the visit after the hospitalisation; and
those who were withdrawn from the study drug. Dose levels
were the following: 3.125 mg bid, 6.25 mg bid, 12.5 mg bid,
and 25 mg bid for carvedilol, and 5 mg bid, 12.5 mg bid,
25 mg bid, and 50 mg bid for metoprolol.2.1. Statistical analysis
Results are expressed as mean±SD unless otherwise spec-
ified. All hypothesis tests reported are two-sided and use a p-
valueb0.05 as significant. Differenceswere assessed by t-tests
for continuous variables and by chi-squared test for categorical
data. Kaplan–Meier survival estimates were calculated.
To assess the impact of the change in beta-blocker dose on
mortality after the HF hospitalisation, changes in the beta-
Table 2
Clinical characteristics of the patients at the visit before the heart failure hospitalisation according to changes in study drug doses
All
n=752
Withdrawn or reduced dose
n=223
Unchanged
n=529
p value withdrawn or reduced
versus unchanged
NYHA class (%) 0.044
I 5 3 6
II 39 34 41
III 46 53 43
IV 9 9 9
Orthopnoea (%) 23 29 21 0.014
Dyspnoea (%) 0.317
Asymptomatic 8 7 9
Walking upstairs 31 28 31
Walking normally 32 32 32
Walking slowly 21 26 19
At rest 8 7 8
Angina (%) 0.483
Yes 18 15 19
No 82 85 81
Well being (%) 0.039
Very good 4 4 4
Good 28 21 31
Average 35 41 33
Poor 23 23 24
Very poor 9 11 8
Pulmonary rales (%) 17 16 18 0.504
Peripheral oedema (%) 0.315
Yes 24 21 25
No 76 79 75
Body weight, kg 79±16 76±15 80±16 0.006
Systolic blood pressure, mm Hg 122±21 118±21 124±21 0.001
Diastolic blood pressure, mm Hg 75±11 74±12 75±11 0.653
Study drug dose, (%) 0.008
C, 3.125 mg bid, M 5 mg bid 18 13 20
C, 6.25 mg bid; M 12.5 mg bid 17 18 16
C, 12.5 mg bid; M 25 mg bid 16 22 13
C, 25 mg bid; M 50 mg bid 48 45 49
Days from randomisation to hospitalisation (%) 0.338
0–74 23 20 25
75–385 25 28 24
386–926 25 27 25
N926 26 25 26
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 blocker dose were included in a multivariable Cox regression
model including baseline factors, shown to be important by
bootstrap methods, as well as variables collected at the visit
before the hospitalisation and causes of hospitalisation that
differed significantly between the beta-blocker dose groups.
The baseline variables included in the model are those re-
tained in ≥70% of the models generated by backward re-
gression from 200 bootstrap samples of the patients in the
study, i.e. random samples of 3029 patients with replace-
ment. No data are available regarding patients' symptoms and
treatment during the HF hospitalisation. The variables en-
tered into the multivariable model were: age, sex, systolic
blood pressure, NYHA class, HF duration, LVEF, serum
creatinine, sodium, and haemoglobin levels, cardiac rhythm
(sinus, paced, atrial fibrillation), furosemide dose, adminis-
tration of antiarrhythmics, digitalis, lipid lowering agents,
study drug, amongst the variables assessed at baseline; body
weight, systolic blood pressure, NYHA class, orthopnoea,well being, study drug dose level, amongst the variables
assessed at the visit prior to the HF hospitalisation; acute
pulmonary oedema, and worsening HF, amongst the causes
of the hospitalisation; and, finally, study drug dose change or
withdrawal.
The adjusted mortality curves in Fig. 3B are produced
from the survivor function of the multivariate Cox regression
analysis. The beta-blocker dose variable (reduced/withdrawn
versus same dose) is a stratified variable, which results in
separately shaped curves (i.e. non-proportional for each).
3. Results
3.1. Follow-up
In COMET, 3029 patients were randomised to carvedilol
(1511 patients) or metoprolol tartrate (1518 patients) and
followed for a median of 58 months (interquartile range 54 to
Table 3
Reasons for admission and precipitating factors causing heart failure
hospitalisation
Withdrawn Reduced dose Same dose p value
N=61 N=162 N=529
Reason for admission
Acute pulmonary
oedema (%)
36.1 20.4 13.6 b0.001
Progressive WHF (%) 78.7 85.2 89.8 0.021
Cause of WHF hospitalisation
Ischaemia (%) 16.4 19.8 17.2 0.730
Atrial fibrillation (%) 14.8 18.5 11.3 0.057
Infection (%) 3.3 10.5 10.6 0.191
Non-compliance (%) 4.9 6.2 4.5 0.702
Renal dysfunction (%) 9.8 5.6 4.9 0.276
Other (%) 44.3 47.5 49.0 0.768
Alcohol excess (%) 1.6 0.0 0.6 0.318
Dietary salt excess (%) 3.3 5.6 3.6 0.513
Hypertension (%) 3.3 5.6 5.3 0.775
Iatrogenic (%) 11.5 5.6 5.9 0.211
More than one causes could be adjudicated. Abbreviations: WHF = wors-
ening heart failure.
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 64). Follow-up was complete for all patients except 5 who
were lost to follow-up and 28 patients who withdrew their
consent during the trial [16]. Patient flow is shown in Fig. 1.
Amongst the 3029 patients included in COMET, 1088 (35.9%,
541 on carvedilol and 547 onmetoprolol) were hospitalised for
HF. Of these, 228 patients (20.9%) were excluded from anal-
ysis as they were not on study medication at the time of
hospitalisation. The cause of the HF hospitalisation of the
remaining 860 patients (421 on carvedilol and 439 on met-
oprolol) was adjudicated as acute pulmonary oedema, wors-
ening HF and study drug related complications in 174 (20%),
637 (74%) and 49 (6%) patients, respectively. Fifty-nine
patients (7%) died during the initial hospitalisation.Fig. 2. Kaplan–Meier curves of mortality subsequent to discharge for the patients
withdrawn, the dose was dose reduced or the dose was left unchanged (same doseFurther analysis is limited to the 752 patients who had a
non-fatal HF hospitalisation caused by acute pulmonary
oedema or worsening HF. Amongst them, 61 patients (8.1%,
19 on carvedilol and 42 on metoprolol) were withdrawn from
their study medication, 162 (21.5%, 84 on carvedilol and 78
on metoprolol) had a reduction in their study drug dose, and
529 (70.3%, 258 on carvedilol and 271 on metoprolol) were
maintained on the same study drug dose at the visit following
the HF hospitalisation, compared to before. Overall, patients
receiving carvedilol were less likely to be withdrawn from
study medication or have a dose reduction, compared to those
on metoprolol ( p=0.018).
3.2. Clinical characteristics.
The characteristics of the patients' hospitalised for HF,
subdivided on the basis of changes in their beta-blocker dose,
are shown in Tables 1 and 2. Since there were no differences
between patients withdrawn from study medication and those
who had the dose reduced, these two groups are shown
together. At baseline, the patients withdrawn from study
medication or who had a dose reduction were less likely to be
males, had more severe symptoms (NYHA class) and more
severe LV systolic dysfunction (LVEF), compared to those
who had their beta-blocker dose unchanged (Table 1). At the
visit prior to the HF hospitalisation, patients withdrawn from
study drug treatment or who reduced their beta-blocker dose
had more severe symptoms (NYHA class), a higher prev-
alence of orthopnoea, poorer well being, a lower body weight
and a lower systolic blood pressure.
The duration of the initial hospitalisation was longer in
the patients who were withdrawn or had a dose reduction,
compared to the others: 27±53 days; median, interquartile
range (IQR), 17, 7–28 days in those withdrawn, 11±9 days,who had an admission for HF, according to whether study medication was
).
ay 10, 2012
Table 4
Variables predictive of all cause mortality post heart failure hospitalisation at
multivariable analysis
HR 95% CI p
Baseline variables
Increasing age (years) 1.035 1.022–1.048 b0.0001
Female versus male 0.749 0.558–1.006 0.0548
Increasing HF duration (months) 1.003 1.001–1.005 0.0006
Increasing LVEF 0.975 0.959–0.99 0.0017
Increasing serum creatinine (μmol/L) 1.003 1.001–1.004 0.0002
Increasing serum sodium (mmol/L) 0.974 0.948–1.000 0.0504
ECG: sinus rhythm versus paced 1.436 0.991–2.08 0.0558
Diuretic dose 81–160 versus ≤40 mg/day 1.591 1.163–2.178 0.0037
Diuretic dose 161–320 versus≤40 mg/day 1.457 0.945–2.246 0.0885
Antiarrhythmics 1.671 1.217–2.296 0.0015
Digitalis 1.816 1.416–2.328 b0.0001
Lipid lowering medication 0.593 0.435–0.808 0.0009
Prior to hospitalisation
Increasing systolic blood pressure (mmHg) 0.984 0.977–0.991 b0.0001
Study drug (beta-blocker) dose change
Reduced/withdrawn versus same dose 1.302 1.023–1.656 0.0318
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 median, IQR, 8, 5–14 days in those with dose reduction
versus 9±8 days, median, IQR, 7, 4–12 days in those with
dose unchanged ( pb0.0001 versus the others).
The potential causes and precipitating factors of the HF
hospitalisations are shown in Table 3. Patients withdrawn
from beta-blocker therapy and, to a lesser extent, those who
had a reduction in their beta-blocker dose were more likely to
be admitted because of acute pulmonary oedema rather than
because of progressive HF. The precipitating factors for HF
hospitalisation did not differ amongst groups.
3.3. Mortality versus changes in beta-blocker dose
Hospitalisation for HF was associated with high mortality.
Mortality was not different between the patients withdrawnFig. 3. Kaplan–Meier mortality curves for the patients withdrawn from study me
change. Mortality curves were unadjusted (3A) or adjusted (3B) for other variablefrom beta-blocker therapy and those who had a dose re-
duction. Thirty-two of the 61 patients (52.5%) withdrawn
from the study drug died and 94 of the 162 patients (58%)
who had a dose reduction also died (hazard ratio=1.32; 95%
confidence intervals [CI], 0.88–1.98; p=0.179). These two
groups were therefore combined for the purposes of
comparison with patients maintained on the same dose of
study drug, of whom 242 of 529 died (45.7%; HR, 1.59; 95%
CI, 1.28–1.98; pb0.0001 for the comparison) (Fig. 2).
Patients who were maintained on the same dose of the
study medication had less severe HF compared to those who
had a dose reduction or who were withdrawn. However, their
mortality risk remained lower after adjustment for baseline
variables and variables collected at the visit before the HF
hospitalisation (HR, 1.30; 95%CI, 1.02–1.66; p=0.0318;
Table 4 and Fig. 3). The other variables which were asso-
ciated with increased mortality after the HF hospitalisation at
multivariable analysis were increasing age, higher serum
creatinine, greater HF duration, lower serum sodium, lower
LVEF, treatment with higher furosemide doses, antiarrhyth-
mic therapy, digitalis therapy, lack of use of statins, lower
systolic blood pressure at the visit prior to hospitalisation
(Table 4).
To address the sensitivity of the analyses to high risk
patients, they were repeated disregarding patients that died
within 4 weeks of hospitalisation (8 patients). The risk of
subsequent mortality remained higher in those patients that
reduced or withdrew study medication compared to those
that were maintained on the same dose (HR, 1.51; 95%CI,
1.22–1.89; pb0.001) but an adjusted analysis resulted in a
non-significant difference between these groups (HR, 1.25;
95%CI, 0.98–1.60; p=0.0711, Table 5).
The mortality rate after hospitalisation in each group was
lower amongst the patients receiving carvedilol, compared to
those on metoprolol (data not shown). No interaction be-
tween the changes in dose after the HF hospitalisation and thedication or who had the dose reduced compared to those who had no dose
s related to mortality at multivariable analysis.
012
Table 5
Variables predictive of all cause mortality post heart failure hospitalisation at
multivariable analysis after excluding subjects who died within 4 weeks of
admission
Baseline variables HR 95%
CI
p
Increasing age
(years)
1.035 1.022,
1.048
b0.0001
Female versus
male
0.764 0.568,
1.028
0.0758
Increasing HF
duration (months)
1.003 1.001,
1.005
0.0006
Increasing LVEF 0.973 0.958,
0.989
0.0009
Increasing serum
creatinine (μmol/L)
1.003 1.001,
1.005
0.0001
Increasing serum
sodium (mmol/L)
0.973 0.947,
1.000
0.0468
ECG: sinus rhythm
versus paced
1.468 1.008,
2.137
0.0451
Diuretic dose 81–160
versus ≤40 mg/day
1.576 1 .15 ,
2.161
0.0047
Antiarrhythmics 1.627 1.178,
2.249
0.0032
Digitalis 1.859 1.447,
2.39
b0.0001
Lipid lowering
medication
0.593 0.434,
0.811
0.0011
Prior to hospitalisation
Increasing systolic
blood pressure (mm Hg)
0.984 0.977,
0.991
b0.0001
Study drug (beta-blocker)
dose change
Reduced/withdrawn
versus same dose
1.253 0.981,
1.601
0.0711
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 beneficial effect on mortality of carvedilol, compared to
metoprolol, was found ( p=0.8436).
4. Discussion
4.1. Background and previous studies
Lack of prescription and use of low doses of beta-blockers
may adversely affect the outcome of HF patients [19–22].
However, the prognostic significance of a dose reduction
and/or withdrawal of beta-blocker therapy may differ in the
patients recently hospitalised for worsening HF. In these
patients, beta-blockade may theoretically have adverse ef-
fects on outcome because of its short-term negative inotropic
effects. [10,11] Accordingly, symptoms of worsening HF
and low cardiac output (weight gain, fatigue, hypotension)
are amongst the most common reasons of discontinuation of
beta-blocker therapy in clinical practice [7,8,23,24]. How-
ever, there is little information on the impact of changes in
beta-blocker therapy after hospitalisation for worsening HF.
A retrospective analysis of the Outcomes of the Prospective
Trial of Intravenous Milrinone for Exacerbations of ChronicHeart Failure (OPTIME-CHF) study [25] reported that,
amongst 212 patients treated with beta-blockers at the time
of the admission for decompensated HF, the 47 patients who
permanently stopped the beta-blocker had a worse outcome
[25]. The 268 of 432 patients receiving beta-blockers at the
time of hospitalisation in the Evaluation Study of Congestive
Heart Failure and Pulmonary Artery Catheterization (ES-
CAPE) had a shorter length of stay and lower 6-month
mortality rate and beta-blocker therapy remained indepen-
dently associated with lower mortality at multivariable
analysis [26]. The Organized Program to Initiate Lifesaving
Treatment in Hospitalized patients with Heart Failure
(OPTIMIZE-HF) showed that carvedilol use at the time of
discharge after a HF hospitalisation is well tolerated and
associated with a reduction in mortality at 60 and 90 days.
[27].
4.2. Beta-blocker withdrawal or dose change in the present
study
COMET is one of the largest and longest trials of patients
with chronic HF on optimal medical treatment. This, there-
fore, allows an assessment of the relation between the
changes in beta-blocker treatment and subsequent outcome.
Our results show that either discontinuation or a reduction
in the dose of the beta-blocker after a HF hospitalisation is
associated with a worse outcome. Though stopping beta-
blockers or reducing their dose was associated with more
severe HF, it remained significantly and independently
associated with increased mortality after adjustment for
baseline variables and for variables obtained at the visit
before the HF hospitalisation. Our results are consistent
with recent analyses from trials [25,27] and registries
[20,26] and show, in addition, that even a reduction in the
beta-blocker dose may be associated with an increase in
mortality.
When the patients who died in the first 4 weeks after the
initial hospitalisation were excluded, discontinuation or dose
reduction in beta-blockers remained associated with in-
creased mortality at univariable but not multivariable
analysis ( p=0.0711). These results show the role of changes
in beta-blocker therapy for short-term outcome. The lower
significance of dose changes at multivariable analysis may be
explained by the reduction in the number of events so that the
power of the model to detect significant changes was reduced
as well.
We did not find any difference in outcome between the
patients who had beta-blocker therapy withdrawn and those
who had a dose reduction. This may reflect the relatively low
number of patients who were completely withdrawn from
beta-blocker therapy (61 patients, 8%). On the other hand,
the association between reduction in beta-blocker dose and
adverse outcome is consistent with post-hoc analysis of this
and other trials [19,21,22]. However, no trial has adequately,
prospectively assessed whether the dose of beta-blocker has
an important effect on clinical outcome.
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 4.3. Carvedilol versus metoprolol tartrate comparison
The COMET trial showed that carvedilol administration is
associated with a lower mortality, compared to metoprolol
tartrate, in patients with HF. Carvedilol did not reduce the rate
of HF hospitalisation, compared to metoprolol, but its effect
on mortality was observed whether or not such a hospitalisa-
tion had occurred. Our present study shows that patients
assigned to carvedilol were less likely to be withdrawn from
beta-blockade or have a reduction in their beta-blocker dose.
This mechanism, though occurring in a relative minority of
patients, is consistent with the beneficial effects on outcome
of carvedilol, compared to metoprolol tartrate.
4.4. Limitations of the study
The present study is a retrospective post-hoc analysis of
the patients who had a HF hospitalisation in COMET. In a
non-randomised analysis it is not possible with certainty
to distinguish between the effects of reducing beta-block-
ade and the reasons for which the beta-blocker was dis-
continued or the dose reduced. We adjusted for available
variables that are markers for disease severity, but this
adjustment may be incomplete. Lastly, no data regarding
the clinical course and treatment during the HF hospitalisa-
tion were collected in COMET. This hinders any inference
regarding the possible effects of in-hospital treatment on
subsequent outcome.
5. Conclusions
We have analysed the relationship between the changes in
beta-blocker dose and outcome of the HF patients studied in
COMET. Hospitalisations for HF were associated with a
high mortality. The patients who were withdrawn from beta-
blocker therapy or who had a dose reduction had a high-
er mortality compared with those who had their dose un-
changed, independent of prognostic variables assessed at
baseline and at the visit before hospitalisation.
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